Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
Cells · 22.12.2023 · 13 (1) · 34
DOI: 10.3390/cells13010034 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 22.12.2023. Verfasst von Lingbin Meng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Carcinoma. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Lingbin Meng from the Ohio State University Comprehensive Cancer Center.
Abstract (Originalsprache)
The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). While localized ccRCC can be cured with surgery, metastatic disease has a poor prognosis. Recently, immunotherapy has emerged as a promising approach for advanced ccRCC. This review provides a comprehensive overview of the evolving immunotherapeutic landscape for metastatic ccRCC. Immune checkpoint inhibitors (ICIs) like PD-1/PD-L1 and CTLA-4 inhibitors have demonstrated clinical efficacy as monotherapies and in combination regimens. Combination immunotherapies pairing ICIs with antiangiogenic agents, other immunomodulators, or novel therapeutic platforms such as bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy are areas of active research. Beyond the checkpoint blockade, additional modalities including therapeutic vaccines, cytokines, and oncolytic viruses are also being explored for ccRCC. This review discusses the mechanisms, major clinical trials, challenges, and future directions for these emerging immunotherapies. While current strategies have shown promise in improving patient outcomes, continued research is critical for expanding and optimizing immunotherapy approaches for advanced ccRCC. Realizing the full potential of immunotherapy will require elucidating mechanisms of response and resistance, developing predictive biomarkers, and rationally designing combination therapeutic regimens tailored to individual patients. Advances in immunotherapy carry immense promise for transforming the management of metastatic ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
- Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
- Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
ORCID-Profile: Katharine A Collier, Zhiwei Hu, Daniel Spakowicz
Förderung
- NCI NIH HHS
- Lingbin Meng from the Ohio State University Comprehensive Cancer Center
Zitieren
APA
Meng, L., Collier, K. A., Wang, P., Li, Z., Monk, P., Mortazavi, A., Hu, Z., Spakowicz, D., Zheng, L., & Yang, Y. (2023). Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells, 13(1), 34. https://doi.org/10.3390/cells13010034
Vancouver
Meng L, Collier KA, Wang P, Li Z, Monk P, Mortazavi A, et al. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells. 2023;13(1):34. doi:10.3390/cells13010034
BibTeX
@article{Meng2023,
author = {Meng, Lingbin and Collier, Katharine A and Wang, Peng and Li, Zihai and Monk, Paul and Mortazavi, Amir and Hu, Zhiwei and Spakowicz, Daniel and Zheng, Linghua and Yang, Yuanquan},
title = {Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma},
journal = {Cells},
year = {2023},
volume = {13},
number = {1},
pages = {34},
doi = {10.3390/cells13010034}
}
EUVIMED